✦ LIBER ✦

Safe and effective two-hour outpatient regimen of hydration and diuresis for the administration of cis-diamminedichloroplatinum (II)

✍ Scribed by Steven E. Vogl; Theodore Zaravinos; Barry H. Kaplan; David Wollner

Book ID: 113146687
Publisher: Elsevier Science
Year: 1981
Weight: 521 KB
Volume: 17
Category: Article
ISSN: 0014-2964
DOI: 10.1016/0014-2964(81)90126-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Toxicity of Cis-diamminedichloroplatinum

Toxicity of Cis-diamminedichloroplatinum II given in a two-hour outpatient regimen of diuresis and hydration

✍ Steven E. Vogl; Theodore Zaravinos; Barry H. Kaplan 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 550 KB

Experimental and clinical studies on the

Experimental and clinical studies on the intraperitoneal administration of cis-diamminedichloroplatinum (II) for peritoneal carcinomatosis caused by gastric cancers

✍ Toshiharu Furukawa; Koichiro Kumai; Tetsuro Kubota; Shinobu Hirahata; Hiroyuki S 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 756 KB

Use of Effective Core Potential Calculat

Use of Effective Core Potential Calculations for the Conformational and Vibrational Study of Platinum(II) Anticancer Drugs. cis -Diamminedichloroplatinum(II) as a Case Study

✍ Fiuza, Sónia M.; Amado, Ana M.; Marques, Maria P. M.; Batista de Carvalho, Luis 📂 Article 📅 2008 🏛 American Chemical Society 🌐 English ⚖ 97 KB

Chemotherapy for advanced head and neck

Chemotherapy for advanced head and neck cancer with the combination adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II): Preliminary assessment of a one-day vs. three-day drug regimen

✍ Edward T. Creagan; Thomas R. Fleming; John H. Edmonson; James N. Ingle; John E. 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 294 KB 👁 3 views

Fourteen patients with advanced head and neck carcinomas received a monthly intravenous regimen of Adriamycin, 40 mg/m2, day 1; cyclophosphamide, 400 mg/m2, day 3; and cis-diamminedichloroplatinum, 20 mg/m2/1 hour, days 1-3 (CAP-3). A regression rate of only 7% (0112 squamous cell carcinomas; 112 ad